Global buyers evaluating CGM manufacturers in China need to look beyond product brochures. A due-diligence process should verify regulatory status, quality systems, performance evidence, manufacturing controls, supply continuity, and post-market responsibilities. These checks help distinguish a product with attractive specifications from a supplier equipped to support a regulated medical-device business.
Confirm the Legal and Manufacturing Entity
First identify exactly who designs, registers, manufactures, and releases the device. A brand owner may differ from the factory, while contract manufacturing can involve several organizations. Ask for the legal manufacturer’s name, manufacturing-site information, applicable licenses or registrations, and documentation showing how responsibilities are divided.
China’s National Medical Products Administration (NMPA) requires medical-device registrants and manufacturers to establish quality management systems appropriate to the devices they produce. Manufacturing activities must also follow the applicable registered or filed product requirements. NMPA has also updated its Good Manufacturing Practice requirements for medical devices, so buyers should verify which manufacturing requirements apply to the supplier and production site at the time of review.
For international procurement teams, companies such as iCan CGM should be evaluated by looking at the specific legal entity, manufacturing site, and responsibilities involved rather than relying on a supplier profile alone.
Examine the Quality System, Not Just the Certificate
ISO 13485:2016 is an important benchmark for medical-device quality management. ISO states that it covers quality management systems for organizations involved in the design and manufacture of medical devices, and the 2016 edition was reviewed and confirmed in 2025.
The next question is how the system works in daily production. Useful evidence includes incoming material inspection, supplier qualification, process validation, equipment maintenance, batch traceability, nonconformance handling, corrective actions, and change control.
These records help answer a practical question: can the manufacturer reproduce the same product consistently after the first commercial order?
Review CGM Performance Evidence in Context
Accuracy is a major consideration, but a published MARD should be read together with the study conditions. Buyers can ask about the reference method, participant population, sensor placement, wear duration, and data used to calculate performance.
For example, the iCan i3 has a 15-day wear life, records glucose results every three minutes, and reports an overall MARD of 8.71% for adults. The iCan i3 is intended for adults and children aged two years and above and has a monitoring range of 2.0-25.0 mmol/L.
These details provide useful context for interpreting the reported performance metric. Buyers should seek similar details from other suppliers rather than comparing isolated numbers.
Check Risk Management and Product Safety
A CGM combines sensing technology, electronics, software, adhesives, and data services, so risk management should cover more than sensor accuracy.
ISO 14971:2019 provides a framework for identifying hazards, evaluating and controlling risks, and monitoring controls throughout the medical-device life cycle. It was reviewed and confirmed in 2025.
Supplier reviews can address sensor insertion, skin contact, communication interruptions, alarm behavior, software failures, data integrity, and product changes. Buyers can also ask how risks are reassessed when materials, software, or manufacturing processes change.
Verify Regulatory Readiness for Target Markets
NMPA compliance matters for products placed on the Chinese market, but global buyers also need to consider the rules of each destination market. For European projects, for example, the EU Medical Device Regulation covers areas including quality management, clinical evaluation, risk management, conformity assessment, and post-market surveillance.
A supplier should explain which markets the product is authorized for, which entity holds each registration, and whether planned changes could affect regulatory status. This is especially relevant to CGM systems because software, labeling, intended use, sensor design, and manufacturing processes may evolve.
Assess Manufacturing Capacity Beyond Factory Size
Production capacity is not simply the number of units a factory can assemble. Buyers should examine critical-material sourcing, production scheduling, inspection resources, yield management, warehousing, traceability, and contingency planning.
Specialized sensors, electronics, adhesives, and other critical components can create upstream bottlenecks even when final assembly lines have available capacity.
Sinocare reports nine global R&D and manufacturing sites, more than 25 million users worldwide, and a business footprint covering 187countries and regions. These figures provide organizational context, but buyers should still verify the specific manufacturing site, capacity, and supply arrangements for the CGM product under consideration. These company-reported figures provide context on organizational scale, but buyers should still verify the specific site and capacity supporting the product under consideration.
Ask About Post-Market Responsibilities
A manufacturer’s responsibilities continue after products leave the factory. Buyers should ask how complaints are recorded, investigated, escalated, and connected to corrective actions. They should also understand procedures for recalls, adverse-event reporting, field updates, software changes, and replacement products.
This is particularly important for buyers serving multiple markets. Clear ownership of regulatory communication and post-market surveillance can reduce uncertainty when a safety or performance issue occurs.
NMPA requirements also address quality responsibilities across manufacturing, change control, product release, after-sales service, complaint handling, adverse-event monitoring, and recalls.
Building a Verification Checklist
When assessing CGM manufacturers in China, buyers can organize due diligence around five questions: Who is the legal manufacturer? What evidence supports product performance? Which systems control quality and regulatory compliance? Can capacity scale without compromising consistency? Who remains responsible after the product reaches the market?
For international buyers, Sinocare’s profile shows the type of organizational information worth reviewing alongside product evidence: manufacturing footprint, R&D resources, market coverage, and the relationship between the brand and its manufacturing operations.
What Global Buyers Should Bring to the Review
Selecting a CGM manufacturer in China should be an evidence-based process. Certifications, registrations, performance studies, production records, supply plans, and post-market procedures should be reviewed together rather than treated as separate checkboxes.
For global buyers, the next step is to request verifiable documentation for the exact device and manufacturing site, then compare that evidence with the regulatory requirements of each target market.





Mobile Industrial Robots — Official Website Screenshot
